Cargando…

Mucopolysaccharidosis Type II: A Kenyan Case Series

Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in b...

Descripción completa

Detalles Bibliográficos
Autores principales: Mungai, L. N. Wainaina, Njeru, C. M., Nyamai, L. A., Maina, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716217/
https://www.ncbi.nlm.nih.gov/pubmed/34976050
http://dx.doi.org/10.1155/2021/2328402
_version_ 1784624275951452160
author Mungai, L. N. Wainaina
Njeru, C. M.
Nyamai, L. A.
Maina, M.
author_facet Mungai, L. N. Wainaina
Njeru, C. M.
Nyamai, L. A.
Maina, M.
author_sort Mungai, L. N. Wainaina
collection PubMed
description Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in body tissues leading to organ failure. Since the laboratories in Kenya do not screen for metabolic diseases, there is the likelihood of assumption that these patients do not exist. These first cases were referred from the eastern part of Kenya where the majority of inhabitants are from the same ethnic community. It was noted that there was increased mortality among boys below the age of 20 years, and hence, the families sought for help in the national referral and teaching hospital. The case series is meant to show that these cases exist and the majority of the patients may be dying before the diagnosis is made. There are no data on MPS2 from Kenya, and the prevalence and incidence are unknown. In this retrospective study, we present a case series of 6 Kenyan boys with MPS2 from a national referral hospital. They were part of 17 patients who had had their blood analyzed for metabolic diseases. All of them were symptomatic with varying degrees of central nervous system involvement. They had undetectable levels of iduronate-2-sulfatase (I2S) enzyme, and three genetic mutations were detected in the IDS gene.
format Online
Article
Text
id pubmed-8716217
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-87162172021-12-30 Mucopolysaccharidosis Type II: A Kenyan Case Series Mungai, L. N. Wainaina Njeru, C. M. Nyamai, L. A. Maina, M. Int J Endocrinol Research Article Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in body tissues leading to organ failure. Since the laboratories in Kenya do not screen for metabolic diseases, there is the likelihood of assumption that these patients do not exist. These first cases were referred from the eastern part of Kenya where the majority of inhabitants are from the same ethnic community. It was noted that there was increased mortality among boys below the age of 20 years, and hence, the families sought for help in the national referral and teaching hospital. The case series is meant to show that these cases exist and the majority of the patients may be dying before the diagnosis is made. There are no data on MPS2 from Kenya, and the prevalence and incidence are unknown. In this retrospective study, we present a case series of 6 Kenyan boys with MPS2 from a national referral hospital. They were part of 17 patients who had had their blood analyzed for metabolic diseases. All of them were symptomatic with varying degrees of central nervous system involvement. They had undetectable levels of iduronate-2-sulfatase (I2S) enzyme, and three genetic mutations were detected in the IDS gene. Hindawi 2021-12-22 /pmc/articles/PMC8716217/ /pubmed/34976050 http://dx.doi.org/10.1155/2021/2328402 Text en Copyright © 2021 L. N. Wainaina Mungai et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mungai, L. N. Wainaina
Njeru, C. M.
Nyamai, L. A.
Maina, M.
Mucopolysaccharidosis Type II: A Kenyan Case Series
title Mucopolysaccharidosis Type II: A Kenyan Case Series
title_full Mucopolysaccharidosis Type II: A Kenyan Case Series
title_fullStr Mucopolysaccharidosis Type II: A Kenyan Case Series
title_full_unstemmed Mucopolysaccharidosis Type II: A Kenyan Case Series
title_short Mucopolysaccharidosis Type II: A Kenyan Case Series
title_sort mucopolysaccharidosis type ii: a kenyan case series
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716217/
https://www.ncbi.nlm.nih.gov/pubmed/34976050
http://dx.doi.org/10.1155/2021/2328402
work_keys_str_mv AT mungailnwainaina mucopolysaccharidosistypeiiakenyancaseseries
AT njerucm mucopolysaccharidosistypeiiakenyancaseseries
AT nyamaila mucopolysaccharidosistypeiiakenyancaseseries
AT mainam mucopolysaccharidosistypeiiakenyancaseseries